Free Trial
→ Satellite Images Spot Potential $10 Trillion Discovery (From Altimetry) (Ad)tc pixel Free TVTX Stock Alerts

Travere Therapeutics (TVTX) Competitors

Travere Therapeutics logo
$42.66 -2.10 (-4.69%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$42.64 -0.02 (-0.06%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TVTX vs. BBIO, RGC, ASND, RDY, and ELAN

Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include BridgeBio Pharma (BBIO), Regencell Bioscience (RGC), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Travere Therapeutics compare to BridgeBio Pharma?

Travere Therapeutics (NASDAQ:TVTX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

In the previous week, Travere Therapeutics had 41 more articles in the media than BridgeBio Pharma. MarketBeat recorded 57 mentions for Travere Therapeutics and 16 mentions for BridgeBio Pharma. Travere Therapeutics' average media sentiment score of 0.31 beat BridgeBio Pharma's score of 0.26 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Travere Therapeutics
25 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
BridgeBio Pharma
7 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

99.9% of BridgeBio Pharma shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Travere Therapeutics has a net margin of -4.00% compared to BridgeBio Pharma's net margin of -144.39%. BridgeBio Pharma's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Travere Therapeutics-4.00% -26.16% -3.71%
BridgeBio Pharma -144.39%N/A -74.43%

Travere Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Travere Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$490.73M8.08-$25.55M-$0.23N/A
BridgeBio Pharma$502.08M26.31-$724.93M-$3.78N/A

Travere Therapeutics currently has a consensus target price of $47.83, indicating a potential upside of 12.13%. BridgeBio Pharma has a consensus target price of $87.71, indicating a potential upside of 30.04%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Travere Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Travere Therapeutics
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.69
BridgeBio Pharma
1 Sell rating(s)
0 Hold rating(s)
24 Buy rating(s)
0 Strong Buy rating(s)
2.92

Travere Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Summary

BridgeBio Pharma beats Travere Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Travere Therapeutics compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Travere Therapeutics (NASDAQ:TVTX) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

Travere Therapeutics has a consensus target price of $47.83, indicating a potential upside of 12.13%. Given Travere Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Travere Therapeutics is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Travere Therapeutics
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.69

In the previous week, Travere Therapeutics had 33 more articles in the media than Regencell Bioscience. MarketBeat recorded 57 mentions for Travere Therapeutics and 24 mentions for Regencell Bioscience. Travere Therapeutics' average media sentiment score of 0.31 beat Regencell Bioscience's score of -0.01 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Regencell Bioscience
0 Very Positive mention(s)
3 Positive mention(s)
18 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Travere Therapeutics
25 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

0.1% of Regencell Bioscience shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Regencell Bioscience has higher earnings, but lower revenue than Travere Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regencell BioscienceN/AN/A-$3.58MN/AN/A
Travere Therapeutics$490.73M8.08-$25.55M-$0.23N/A

Regencell Bioscience has a net margin of 0.00% compared to Travere Therapeutics' net margin of -4.00%. Regencell Bioscience's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Regencell BioscienceN/A N/A N/A
Travere Therapeutics -4.00%-26.16%-3.71%

Regencell Bioscience has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.

Summary

Travere Therapeutics beats Regencell Bioscience on 7 of the 13 factors compared between the two stocks.

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Travere Therapeutics (NASDAQ:TVTX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Travere Therapeutics has a net margin of -4.00% compared to Ascendis Pharma A/S's net margin of -30.85%. Ascendis Pharma A/S's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Travere Therapeutics-4.00% -26.16% -3.71%
Ascendis Pharma A/S -30.85%N/A -19.63%

Travere Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Travere Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$490.73M8.08-$25.55M-$0.23N/A
Ascendis Pharma A/S$720.13M21.32-$258M-$4.40N/A

Travere Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

In the previous week, Travere Therapeutics had 47 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 57 mentions for Travere Therapeutics and 10 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.32 beat Travere Therapeutics' score of 0.31 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Travere Therapeutics
25 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ascendis Pharma A/S
6 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Travere Therapeutics presently has a consensus target price of $47.83, indicating a potential upside of 12.13%. Ascendis Pharma A/S has a consensus target price of $291.56, indicating a potential upside of 18.45%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Travere Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Travere Therapeutics
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.69
Ascendis Pharma A/S
1 Sell rating(s)
0 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.95

Summary

Ascendis Pharma A/S beats Travere Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Travere Therapeutics compare to Dr. Reddy's Laboratories?

Travere Therapeutics (NASDAQ:TVTX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Dr. Reddy's Laboratories has a net margin of 16.41% compared to Travere Therapeutics' net margin of -4.00%. Dr. Reddy's Laboratories' return on equity of 15.89% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Travere Therapeutics-4.00% -26.16% -3.71%
Dr. Reddy's Laboratories 16.41%15.89%10.73%

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$490.73M8.08-$25.55M-$0.23N/A
Dr. Reddy's Laboratories$3.81B2.94$663M$0.7717.46

Travere Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.

In the previous week, Travere Therapeutics had 55 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 57 mentions for Travere Therapeutics and 2 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.84 beat Travere Therapeutics' score of 0.31 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Travere Therapeutics
25 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Dr. Reddy's Laboratories
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Travere Therapeutics currently has a consensus target price of $47.83, indicating a potential upside of 12.13%. Dr. Reddy's Laboratories has a consensus target price of $16.90, indicating a potential upside of 25.70%. Given Dr. Reddy's Laboratories' higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Travere Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Travere Therapeutics
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.69
Dr. Reddy's Laboratories
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Dr. Reddy's Laboratories beats Travere Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Travere Therapeutics compare to Elanco Animal Health?

Travere Therapeutics (NASDAQ:TVTX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

In the previous week, Travere Therapeutics had 31 more articles in the media than Elanco Animal Health. MarketBeat recorded 57 mentions for Travere Therapeutics and 26 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.66 beat Travere Therapeutics' score of 0.31 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Travere Therapeutics
25 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Elanco Animal Health
8 Very Positive mention(s)
2 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Travere Therapeutics currently has a consensus target price of $47.83, indicating a potential upside of 12.13%. Elanco Animal Health has a consensus target price of $28.20, indicating a potential upside of 17.18%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Travere Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Travere Therapeutics
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.69
Elanco Animal Health
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77

Travere Therapeutics has a net margin of -4.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.37% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Travere Therapeutics-4.00% -26.16% -3.71%
Elanco Animal Health -4.95%7.37%3.64%

97.5% of Elanco Animal Health shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Travere Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.

Travere Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Travere Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$490.73M8.08-$25.55M-$0.23N/A
Elanco Animal Health$4.72B2.54-$232M-$0.48N/A

Summary

Elanco Animal Health beats Travere Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Travere Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TVTX vs. The Competition

Export
MetricTravere TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.16B$3.45B$6.31B$12.15B
Dividend YieldN/A2.22%2.78%5.25%
P/E Ratio-185.4733.4528.4527.01
Price / Sales8.08294.48528.5676.85
Price / Cash123.60125.2843.3053.97
Price / Book40.257.309.826.89
Net Income-$25.55M$23.67M$3.55B$333.11M
7 Day PerformanceN/AN/AN/A0.14%
1 Month Performance34.66%4.95%5.20%6.79%
1 Year Performance108.76%75.81%40.39%38.93%

Travere Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TVTX
Travere Therapeutics
2.0289 of 5 stars		$42.66
-4.7%		$47.83
+12.1%		+110.9%$4.16B$490.73MN/A460
BBIO
BridgeBio Pharma
3.3477 of 5 stars		$75.61
+3.2%		$87.38
+15.6%		+88.3%$14.66B$502.08MN/A400
RGC
Regencell Bioscience
0.4898 of 5 stars		$29.12
+5.9%		N/AN/A$14.40BN/AN/A10
ASND
Ascendis Pharma A/S
3.7381 of 5 stars		$227.21
-0.9%		$291.56
+28.3%		+52.6%$14.17B$814.57MN/A1,189
RDY
Dr. Reddy's Laboratories
3.8599 of 5 stars		$13.96
+2.1%		$16.90
+21.1%		-0.5%$11.65B$3.81B18.1227,811

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TVTX) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever
"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...
Chaikin Analytics | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Is the SpaceX IPO “Rigged?”
The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...
The Oxford Club | Sponsoredtc pixel
Why I flew on a tiny helicopter next to a potential nuclear bomb target
Satellite Confirms: Elon Musk Activating Strange 'Dark Energy' Across U.S. South Confirmed by satellites 30...
Altimetry | Sponsoredtc pixel
The AI stocks about to become worthless (and one that isn't)
Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...
InvestorPlace | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Hey, Have You Claimed Your Rebate Check??
The U.S. has already collected $195 billion in tariff revenue this year, with projections reaching $400 billio...
Angel Publishing | Sponsoredtc pixel